Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation

Resuscitation. 2014 Oct;85(10):1337-41. doi: 10.1016/j.resuscitation.2014.06.032. Epub 2014 Jul 14.

Abstract

Introduction: We compare the outcomes for patients who received esmolol to those who did not receive esmolol during refractory ventricular fibrillation (RVF) in the emergency department (ED).

Methods: A retrospective investigation in an urban academic ED of patients between January 2011 and January 2014 of patients with out-of-hospital or ED cardiac arrest (CA) with an initial rhythm of ventricular fibrillation (VF) or ventricular tachycardia (VT) who received at least three defibrillation attempts, 300mg of amiodarone, and 3mg of adrenaline, and who remained in CA upon ED arrival. Patients who received esmolol during CA were compared to those who did not.

Results: 90 patients had CA with an initial rhythm of VF or VT; 65 patients were excluded, leaving 25 for analysis. Six patients received esmolol during cardiac arrest, and nineteen did not. All patients had ventricular dysrhythmias refractory to many defibrillation attempts, including defibrillation after administration of standard ACLS medications. Most received high doses of adrenaline, amiodarone, and sodium bicarbonate. Comparing the patients that received esmolol to those that did not: 67% and 42% had temporary return of spontaneous circulation (ROSC); 67% and 32% had sustained ROSC; 66% and 32% survived to intensive care unit admission; 50% and 16% survived to hospital discharge; and 50% and 11% survived to discharge with a favorable neurologic outcome, respectively.

Conclusion: Beta-blockade should be considered in patients with RVF in the ED prior to cessation of resuscitative efforts.

Keywords: Cardiac arrest; Cardiopulmonary resuscitation; Defibrillation.

Publication types

  • Evaluation Study
  • Observational Study

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists / therapeutic use*
  • Cardiopulmonary Resuscitation*
  • Female
  • Heart Arrest / complications
  • Humans
  • Male
  • Middle Aged
  • Propanolamines / therapeutic use*
  • Retrospective Studies
  • Treatment Failure
  • Ventricular Fibrillation / drug therapy*
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / therapy

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Propanolamines
  • esmolol